Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety of Adafosbuvir and Odalasvir
NCT03155893Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adafosbuvir and odalasvir in hepatitis C (HCV) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: QT/QTc Interval Change at Day 16, PR Interval Change at Day 16 and 1 more. Started May 2017; status: completed.
02
Drugs
adafosbuvirodalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03155893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155893.